| Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity. | |
| | |
MedLine Citation:
|
PMID: 21421717 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
New antitumor agents have resulted in significant survival benefits for cancer patients. However, several agents may have serious cardiovascular side effects. Left ventricular ejection fraction measurement by (99m)Tc multigated radionuclide angiography is regarded as the gold standard to measure cardiotoxicity in adult patients. It identifies left ventricular dysfunction with high reproducibility and low interobserver variability. A decrease in left ventricular ejection fraction, however, is a relatively late manifestation of myocardial damage. Nuclear cardiologic techniques that visualize pathophysiologic processes at the tissue level could detect myocardial injury at an earlier stage. These techniques may give the opportunity for timely intervention to prevent further damage and could provide insights into the mechanisms and pathophysiology of cardiotoxicity caused by anticancer agents. This review provides an overview of past, current, and promising newly developed radiopharmaceuticals and describes the role and recent advances of scintigraphic techniques to measure cardiotoxicity. Both first-order functional imaging techniques (visualizing mechanical [pump] function), such as (99m)Tc multigated radionuclide angiography and (99m)Tc gated blood-pool SPECT, and third-order functional imaging techniques (visualizing pathophysiologic and neurophysiologic processes at the tissue level) are discussed. Third-order functional imaging techniques comprise (123)I-metaiodobenzylguanidine scintigraphy, which images the efferent sympathetic nervous innervations; sympathetic neuronal PET, with its wide range of tracers; (111)In-antimyosin, which is a specific marker for myocardial cell injury and necrosis; (99m)Tc-annexin V scintigraphy, which visualizes apoptosis and cell death; fatty-acid-use scintigraphy, which visualizes the storage of free fatty acids in the lipid pool of the cytosol (which can be impaired by cardiotoxic agents); and (111)In-trastuzumab imaging, to study trastuzumab targeting to the myocardium. To define the prognostic importance and clinical value of each of these functional imaging techniques, prospective clinical trials are warranted. |
| | |
Authors:
|
Lioe-Fee de Geus-Oei; Annelies M C Mavinkurve-Groothuis; Louise Bellersen; Martin Gotthardt; Wim J G Oyen; Livia Kapusta; Hanneke W M van Laarhoven |
Related Documents
:
|
21344247 - Transcatheter valve repair/implantation. 7053657 - Neurohumoral observations and the gastrointestinal tract. 21360687 - High-resolution x-ray microtomography for three-dimensional imaging of cardiac progenit... 21301137 - Cardiac magnetic resonance imaging: choice of the year: which imaging modality is best ... 23143567 - Real-time 1-d/2-d transient elastography on a standard ultrasound scanner using mechani... 21969707 - Evaluation of apparent diffusion coefficient mappings in amnestic mild cognitive impair... |
Publication Detail:
|
Type: Journal Article; Review Date: 2011-03-18 |
Journal Detail:
|
Title: Journal of nuclear medicine : official publication, Society of Nuclear Medicine Volume: 52 ISSN: 1535-5667 ISO Abbreviation: J. Nucl. Med. Publication Date: 2011 Apr |
Date Detail:
|
Created Date: 2011-03-28 Completed Date: 2011-05-31 Revised Date: 2013-05-08 |
Medline Journal Info:
|
Nlm Unique ID: 0217410 Medline TA: J Nucl Med Country: United States |
Other Details:
|
Languages: eng Pagination: 560-71 Citation Subset: IM |
Affiliation:
|
Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. L.deGeus-Oei@nucmed.umcn.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
3-Iodobenzylguanidine
/
diagnostic use Annexin A5 / diagnostic use Anthracyclines / adverse effects Antibodies, Monoclonal / adverse effects, diagnostic use Antibodies, Monoclonal, Humanized Antineoplastic Agents / adverse effects*, therapeutic use Fatty Acids / chemistry Gated Blood-Pool Imaging Heart / innervation, radionuclide imaging Heart Diseases / chemically induced*, diagnosis, radionuclide imaging* Humans Neoplasms / complications*, drug therapy Organometallic Compounds / diagnostic use Radiopharmaceuticals / diagnostic use Sympathetic Nervous System / radionuclide imaging Tomography, Emission-Computed, Single-Photon |
| Chemical | |
Reg. No./Substance:
|
0/Annexin A5; 0/Anthracyclines; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antineoplastic Agents; 0/Fatty Acids; 0/Organometallic Compounds; 0/Radiopharmaceuticals; 138660-99-8/imciromab pentetate; 77679-27-7/3-Iodobenzylguanidine; P188ANX8CK/trastuzumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets.
Next Document: Searching for alternatives to full kinetic analysis in 18F-FDG PET: an extension of the simplified k...